Avalere Health, a key player in the healthcare strategy sector, has announced Sarah Hall as its new President of US Marketing. This follows her impressive 13-year tenure at FCB Health New York, where she served as Managing Partner and later as President. Hall has also led teams at companies like Saatchi & Saatchi Wellness and Arnold Worldwide.
Her deep experience in direct-to-consumer (DTC) marketing positions her well for the challenges ahead. In her new role, Hall will steer Avalere toward innovative DTC strategies while fostering strong partnerships in a rapidly changing US healthcare landscape.
Amar Urhekar, CEO of Avalere, expressed confidence in Hall’s ability to make a notable impact. He stated, “Sarah brings exceptional leadership and a knack for bringing out the best in people. Her talent will help us develop solutions that resonate with patients.”
As President, Hall will oversee Avalere’s marketing teams focused on Development, Creative, Media, and Access Marketing. Her goal is to elevate success for biopharmaceutical and health tech partners amid political complexities and digital advances. This effort includes engaging patients on a wider scale.
Avalere’s marketing agency emphasizes areas like rare diseases, oncology, precision medicine, specialty pharmaceuticals, and medical devices. Hall aims to enhance Avalere’s existing strengths in product launches and data-driven marketing.
In her own words, Hall is enthusiastic about joining the leadership team. She is inspired by Avalere’s collaborative culture, combining marketing, media, AI, and policy insights to create meaningful changes for clients and patients alike.
Interestingly, as healthcare continues to evolve, nearly 75% of patients prefer accessing information about treatments and services online, according to a recent survey by the Harris Poll. This shift emphasizes the need for strong DTC approaches in healthcare marketing. With Hall at the helm, Avalere is set to meet this demand creatively and effectively.
As healthcare evolves with ongoing technological advancements and regulatory changes, Hall’s leadership could be pivotal in keeping Avalere ahead of the curve. For further insights, see Avalere’s strategic outlook on patient engagement [here](https://www.avalere.com).
